Study to Evaluate Safety and Activity of TRL345 in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

September 14, 2023

Primary Completion Date

December 23, 2024

Study Completion Date

December 23, 2024

Conditions

Healthy Volunteers

Interventions

DRUG

TRL345, a human monoclonal antibody

Anti-Human Cytomegalovirus (HCMV) IgG1κ Human Monoclonal Antibody

Trial Locations (1)

Celerion, Tempe

All Listed Sponsors

collaborator

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

lead

Trellis Bioscience LLC

INDUSTRY

NCT05408091 - Study to Evaluate Safety and Activity of TRL345 in Healthy Volunteers | Biotech Hunter | Biotech Hunter